A research article describing a preclinical drug-discovery study that screened CNS-focused compounds and followed a lead through cellular and mouse remyelination assays.
Key Takeaways
- In terms of pharmacokinetics, CN045 is CNS-penetrable with low cytotoxicity
- CN045 has a short half-life in vivo
- Is an inflammatory-mediated demyelinating disease of the central nervous system (CNS)